Skip to content
Screener

Collegium Pharmaceutical, Inc. COLL Symproic — Finite-Lived Intangible Assets, Net

Other product segments

Azstarys
$627.52M
Jornay PM
$482.01M-14.8%
Symproic and other
$42.5M-14.6%
Belbuca
$37.7M-66.7%

Similar metrics at other companies

Abercrombie & Fitch logo
ANFAmericas — Finite-Lived Intangible Assets, Net
$2.9M0.0%
Abercrombie & Fitch logo
ANFEMEA — Finite-Lived Intangible Assets, Net
$14.6M-11.0%
Sirius XM logo
SIRISiriusXM — Finite-Lived Intangible Assets, Net
$57M-40.0%
SPX Technologies logo
SPXCRevenues — Finite-Lived Intangible Assets, Net
$601.9M+61.9%
Sonic Automotive logo
SAHFranchised Dealerships — Finite-Lived Intangible Assets, Net
$394.5M+19.1%
Sonic Automotive logo
SAHPowersports Dealerships — Finite-Lived Intangible Assets, Net
$27.3M0.0%

Other financials

Income statement

See full
Revenue$199.9M+6.3%
Gross profit$110.3M+1.8%
Operating income$3.7M-89.5%
Net income-$15.1M-226%
EPS (diluted)-$0.46-235%

Balance sheet

See full
Cash & equivalents$150.4M+8.8%
Total debt$5.0M-19.8%
Total equity$311.9M+34.3%
Total assets$2.1B+34.1%

Cash flow

See full
Operating cash flow$71.3M-1.5%
CapEx$496.0K+663%
Free cash flow$70.8M-2.1%

Valuation

See full
Market cap$955.82M-16.0%
Enterprise value$810.41M-19.5%
P/E20×-11.4×
P/S1.2×-0.4×

Profitability

See full
Gross margin60%+3.3pp
Operating margin19.5%+1.1pp
Net margin5.9%+0.8pp
FCF margin40.6%+10.8pp

Returns & leverage

See full
Return on equity17.6%+1.4pp
Debt / equity0.0×
Current ratio-0.2×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.

The source filing: Collegium Pharmaceutical, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:34 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001628280-26-053851
Line itemJune 30, 2026 / CostJune 30, 2026 / Accumulated AmortizationJune 30, 2026 / Carrying AmountDecember 31, 2025 / CostDecember 31, 2025 / Accumulated AmortizationDecember 31, 2025 / Carrying Amount
Jornay PM$635,000$(152,986)$482,014$635,000$(111,072)$523,928
Azstarys635,000(7,480)627,520
Belbuca360,000(322,305)37,695360,000(284,607)75,393
Nucynta Products521,170(521,170)521,170(493,478)27,692
Symproic70,000(31,145)38,85570,000(27,503)42,497
Total intangible assets$2,221,170$(1,035,086)$1,186,084$1,586,170$(916,660)$669,510

Item 1. Condensed Consolidated Financial Statements (Unaudited).

FAQ

What is Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net?
Collegium Pharmaceutical, Inc. (COLL) reported symproic — finite-lived intangible assets, net of $38.86M in Q2 2026.
How has Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net changed year-over-year?
Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net decreased by 15.8% year-over-year, from $46.14M to $38.86M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net?
Over 3 years (2022 to 2025), Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net has grown at a -12.3% compound annual growth rate (CAGR), from $268.35M to $180.92M.
What does symproic — finite-lived intangible assets, net mean?
The carrying value of finite-lived intangible assets associated with Symproic, calculated as the gross cost minus accumulated amortization and any impairment charges. It represents the remaining unamortized economic value of the asset on the balance sheet.

Ask your AI about Collegium Pharmaceutical, Inc.'s symproic — finite-lived intangible assets, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude